Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Meiji Co., Ltd. produces and sells milk, dairy, confectioneries, and food. Its products include cheese, ice cream, chocolate, infant formula, whey protein, beauty supplements, and yogurt. The company was founded on December 21, 1917 and is headquartered in Tokyo, Japan.

Fujisawa Pharmaceutical Co. Ltd. develops, manufactures and markets pharmaceuticals and medical products. The Group's principal activity is the manufacture and sale of pharmaceuticals, medical equipment and supplies, home care products, chemicals and animal health products. Pharmaceuticals (ethical drugs, OTC drugs, toilet goods) accounted for 91% of fiscal 2002 revenues and other operations (food additives, industrial chemicals, animal drugs, research and clinical reagents). It was founded in 1894 and was headquartered in Osaka, JP

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Kirin Brewery Co., Ltd. engages in the manufacture of alcoholic beverages. Its products include beer, sparkling liquor, chuhai, gin, and whiskey. The company was founded in 1901 and is headquartered in Tokyo, Japan.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Tianhao Biomedical Technology (Suzhou) Co., Ltd., established on 2010-12-30, Business scope includes research and development:biological reagent,In Vitro Diagnostic Kit,Pharmaceutical Intermediates,medical instruments;Technology development within the specialized field of biotechnology,technology transfer,technical consulting,Technical Services;Sales:Experimental Biological Reagents,Laboratory equipment,Class I medical device;Engage in the import and export of the above commodities and technologies.Production of Class III Medical Devices;Production of Class I Medical Devices;Sales of Class II Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Non-residential real estate leases;property management;Conference and Exhibition Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Manufactures pharmaceuticals

Asahi Kasei Medical Co. Ltd. engages in the development, manufacture and sale of medical devices. It also engages in the development, manufacture and sale of dialyzers, therapeutic apheresis products, leukocyte reduction filters and virus removal filters. The company was founded on July 24, 1974 and is headquartered in Tokyo, Japan.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

SyStemix develops cellular and cell-based gene therapies for cancer, AIDS, and genetic diseases based on the use of isolated, expanded, and gene-modified hematopoietic stem cells. The company is based in Palo Alto, California. SyStemix, Inc. was acquired by Novartis AG. In February 1997, SyStemix completed a merger with Novartis Biotech Holding Corp., an indirect wholly owned subsidiary of Novartis, Inc. Novartis shuttered Systemix in 2000.

Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Manufactures sugar, preservatives, spices, pigments and coffee sugar

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

SunBio, Inc. develops biosimilars, biopharmaceuticals, medical devices, and cosmetic products based on proprietary technologies comprised of site-directed pegylation of proteins, cell engineering technology, and novel pegylation technologies. The company was founded on June 10, 1997 and is headquartered in Gunpo-si, South Korea.

Trustees of Dartmouth College, part of Dartmouth College, is a company headquartered in Hanover, NH. The firm operates higher education institutes. It was founded in 1769.

Tianjin Kunjian Biopharmaceutical Co., Ltd., established on 2010-09-01, The scope of business includes chemical medicine,Research and development of biopharmaceuticals and medical devices,Technology Transfer and Technology Consulting,and provide related services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)